Overview
Our Mission
Neunos Ltd is combining the latest advances of neuroscience with cutting-edge microelectronic approaches in order to provide a therapeutic solution based on oscillatory interference with ongoing neuronal network activity. We develop a minimally-invasive, implantable seizure suppression system, which automatically detects the onset of epileptic seizures and promptly terminates them by transcranial electrical stimulation before fatal accidents evolve.
Treating epileptic seizures is our main focus, however we are continuously looking for new opportunities and alternative perspectives to deepen our knowledge in neuropsychiatric disorders, and find new non-pharmaceutical therapeutic approaches.
Quality management
The main goal of our company is to create, develop and optimize a new, innovative technology, which is primarily capable to treat epileptic seizures, by meeting the customer requirements and minimizing the risks.
In order to meet our high quality requirements, all of our activities are done according to the released European (EU MDR) and American (21CFR Part820) regulations. Above these, our quality management system has been created, maintained and continuously developed in accordance with the ISO13485:2016 standard.
For more details, please contact us.
VISION
To stop seizures, depression, and other brain disorders from limiting a full life.
MISSION
To pioneer Oscillotherapy™ as a minimally invasive way of radically altering the course of life with brain disorders.
SOLUTION
Neunos is a breakthrough solution for people with epilepsy and certain neuropsychiatric diseases.
Timeline
Research on transcranial electrical stimulation in seizure termination starts Concept of closed-loop epilepsy treatment is established (Berényi et al, Science) IP Protection of ISP™ stimulation (Berényi & Buzsáki) Efficacy of long-term seizure supression (Kozák et al, Sci Rep) Human efficacy criteria established (Vöröslakos et al, Nat Comm) Incorporation of Neunos Ltd, & Launch of ISP SeizureStop™ development project Exclusive license agreement with New York Univerity and Szeged University on the use of ISP™ technology First prototype of ISP™ SeizureStop™ device Launch of human safety investigations Implantable Device development starts First prototype device to explore neuropsychiatric applications of ISP stimulation Pilot clinical studies to be launched Pivotal clinical trial to be launched Obtaining CE-mark Obtaining FDA approval Market introduction
2010
2012
2016
2017
January 2018
March-May 2018
September 2019
November 2019
November 2021
June 2022
June 2023
2024
Future
Future
Future
Future
More information
TRUSTFUL BACKGROUND
Science-based breakthrough in halting epileptic seizures by a team of expert neuroscientists:
- Convincing results from clinical investigation to halt epileptic seizures.
Neunos has achieved convincing results from a clinical investigation which has proven to stop seizures as they occur in epileptic patients.
- Based on solid science, 10 years of research.
Neunos is based on 10 years of dedicated research in the field of neuromodulation and Oscillotherapy™. The path from scientific discovery to product invention has been purely organic, built on solid science.
- Invented by respected neuroscientists, surrounded by experts.
The technology was co-invented by Antal Berényi, PhD and György Buzsáki, PhD, highly respected neuroscientists. The Neunos team includes fellow neuroscientists, engineers, researchers, and technology experts, as well as support from key opinion leaders such as Orrin Devinsky, M.D., director of the NYU Comprehensive Epilepsy Center.
PATENTED TECHNOLOGY
Patented closed-loop technology to detect and correct pathological brain waves as they occur:
- Patented technology, Intersectional Short Pulse (ISP) stimulation.
Neunos is based on the patented stimulation concept, Intersectional Short Pulse stimulation (ISP). As a cognitive episode or seizure emerges, derailed brain waves are targeted by intense counter waves to restore equilibrium and halt the episode as it occurs.
- Closed-loop platform responsive to immediate need without external intervention.
Neunos is closed-loop platform technology which provides 24/7 episode detection and requires no external intervention. Oscillotherapy™ is continuously and autonomously tailored based on a patient’s immediate need, wellness, and disease regression.
- Based on a complex and unique mathematical model.
A complex and unique mathematical model detects brain wave disruptions with high reliability and designs a response personalized to the patient’s immediate need.
BREAKTHROUGH APPLICATION
Minimally invasive application with infinite possibilities for treating epilepsy and certain neuropsychiatric disorders:
- Unique spatial application without limits.
The unique spatial application of Neunos makes our technology limitless. Steerable pulses are able to correct an infinite number of brain waves without the need to modify or adjust anything.
- Minimally invasive application without brain surgery or drugs.
Neunos doesn’t require brain surgery or drugs. Minimally invasive neuromodulation devices located underneath the skin deliver precision counter waves deep inside he brain with effective intensity.
- Millisecond application with high precision and targeted intensity.
Neunos is applied using a millisecond precision approach. Oscillotherapy™ occurs with precise timing and intensity, exclusively to derailed brain wave(s). No additional areas of the body are impacted and therapy ceases once the neurological episode subsides.